The Food & Drug Administration (FDA) is taking another look at oral bisphosphonate medications, a class of drugs that includes Fosamax, Actonel, Boniva, and Reclast. There continues to be concern that the drugs, used to prevent osteoporosis in post-menopausal women, are associated with a specific type of femur fracture.
According to a notice posted on the FDA’s Web site, in June 2008 the agency requested information from all bisphosphonate drug manufacturers regarding the potential for atypical femur fractures. According to the FDA, a review of available data did not show an increase in this risk in women using these medications. (more…)
